CLINICAL TRIALS PROFILE FOR CLONAZEPAM

All Clinical Trials for CLONAZEPAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00025740 ↗	Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder	Completed	National Institute of Mental Health (NIMH)	Phase 4	2001-10-01	Post-Traumatic Stress Disorder (PTSD) is an anxiety disorder that follows exposure to an extremely traumatic stressors. PTSD is associated with serious symptoms. While numerous approaches have been used to treat PTSD, these treatments have several limiting factors. This study will evaluate a combination of the drugs clonazepam and paroxetine for the treatment of PTSD symptoms. The main goal of treatment in patients with PTSD is to significantly reduce symptom severity and improve functioning. While numerous approaches have been used to treat PTSD, these treatments are limited by variable response rates, up to a 6-week lag period before clinical response, and sub-optimal side effect profile, including possible worsening of anxiety and insomnia prior to clinical response. The proposed study will examine whether combined treatment with a benzodiazepine (clonazepam) and a selective serotonin reuptake inhibitor (paroxetine) in patients with PTSD will accelerate the onset of clinical response. A second goal is to evaluate whether the rapid and clinically meaningful benefits are sustained until the end of the study, despite tapering off the benzodiazepine at the midpoint of the study. The safety and tolerability of a combination of paroxetine and clonazepam will be compared to paroxetine and placebo (an inactive pill) in the treatment of PTSD. Participants in this study will be randomly assigned to receive either paroxetine plus clonazepam or paroxetine plus a placebo for 12 weeks. Participants will have weekly clinic visits for the first 4 weeks of the study and every other week for the last 8 weeks. Symptoms of PTSD, anxiety, and depression will be evaluated and drug side effects will be noted during the follow-up visits.
NCT00031317 ↗	Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression	Completed	National Institute of Mental Health (NIMH)	Phase 4	2002-02-01	The purpose of this study is to examine the safety and effectiveness of the drug combination paroxetine and clonazepam in treating people with panic disorder (PD) and major depression. The main goal in treating people with PD is to rapidly reduce symptom severity and improve functioning. While numerous drug therapies have been used to treat PD, these treatments are limited by variable response rates and suboptimal side effect profiles. Evidence suggests that clonazepam given with a selective serotonin reuptake inhibitor (SSRI) can facilitate a rapid reduction in PD symptoms. However, it is unclear whether comorbid depression influences treatment response to the clonazepam and SSRI regimen. This study will examine whether combined treatment with clonazepam and the SSRI paroxetine will accelerate clinical response in participants with PD and comorbid depression. This study will also examine whether the benefits of treatment will be sustained until the end of the study despite tapering of clonazepam at the midpoint of the study. Participants in this study will be screened with medical and psychiatric interviews, a physical examination, electrocardiogram (ECG), and blood tests. Participants will then be randomly assigned to receive either paroxetine plus clonazepam or paroxetine plus placebo (an inactive pill) for 12 weeks. Participants will have weekly clinic visits during which symptoms and drug side effects will be checked and an interview to evaluate panic disorder and depression symptoms will be conducted.
NCT00118417 ↗	Therapies for Treatment-Resistant Panic Disorder Symptoms	Completed	National Institute of Mental Health (NIMH)	Phase 2/Phase 3	1999-03-01	This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
NCT00118417 ↗	Therapies for Treatment-Resistant Panic Disorder Symptoms	Completed	Massachusetts General Hospital	Phase 2/Phase 3	1999-03-01	This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
NCT00238914 ↗	Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1999-08-01	The overall goal of this research project is to test a newly developed behavioral therapy to enhance the efficacy of naltrexone maintenance and make it a viable alternative to methadone maintenance or detoxification methods for treatment of opiate dependence. HYPOTHESES: 1. Outpatient treatment with Behavioral Naltrexone Therapy will yield a lower rate of relapse to illicit opiates compared to naltrexone plus Compliance Enhancement (CE) Therapy. 2. Lifetime history of depression will predict dysphoria and non-compliance with naltrexone.

Clinical Trial Conditions for CLONAZEPAM

Condition Name

Condition Name for CLONAZEPAM
Intervention	Trials
Schizophrenia	9
Burning Mouth Syndrome	8
Psychotic Disorders	5
REM Sleep Behavior Disorder	4

Condition MeSH

Condition MeSH for CLONAZEPAM
Intervention	Trials
Disease	16
Mental Disorders	11
Syndrome	9
Schizophrenia	9

Clinical Trial Locations for CLONAZEPAM

Trials by Country

Trials by Country for CLONAZEPAM
Location	Trials
United States	30
Spain	6
Korea, Republic of	4
Switzerland	4
Mexico	3

Trials by US State

Trials by US State for CLONAZEPAM
Location	Trials
New York	9
Massachusetts	4
Ohio	3
California	3
Maryland	3

Clinical Trial Progress for CLONAZEPAM

Clinical Trial Phase

Clinical Trial Phase for CLONAZEPAM
Clinical Trial Phase	Trials
PHASE4	3
PHASE2	1
Phase 4	26

Clinical Trial Status

Clinical Trial Status for CLONAZEPAM
Clinical Trial Phase	Trials
Completed	34
Unknown status	10
Recruiting	9

Clinical Trial Sponsors for CLONAZEPAM

Sponsor Name

Sponsor Name for CLONAZEPAM
Sponsor	Trials
Instituto de Investigación Marqués de Valdecilla	5
Fundación Marques de Valdecilla	5
New York State Psychiatric Institute	5

Sponsor Type

Sponsor Type for CLONAZEPAM
Sponsor	Trials
Other	105
Industry	15
NIH	9

Clonazepam Clinical Trials Update, Market Analysis, and Global Revenue Projections (2026–2035)

Last updated: July 25, 2026

Clonazepam is an older, long-established benzodiazepine with continued global demand driven by chronic indications (epilepsy, panic disorder), generics dominance, and limited probability of meaningful late-stage “new entrant” clinical development economics in most geographies. Publicly disclosed late-stage pipeline updates are sparse versus newer CNS assets, with the dominant commercial reality being mature off-patent status in major markets and sustained price pressure.

What is clonazepam’s current clinical trial landscape (latest updates and active studies)?

Short answer: Public late-stage development activity for clonazepam is limited. Most observable trial activity clusters around small studies (new formulations, dose optimization, or comparative pharmacology) rather than Phase 3 pivotal programs designed for new regulatory indications.

Trial activity patterns to expect for an off-patent benzodiazepine

• Reformulation or switching studies: oral bioavailability, taste/mouthfeel, or rapid-onset versus standard release comparisons.
• Safety and pharmacovigilance add-ons: real-world tolerability, driving impairment metrics, withdrawal protocols.
• Subpopulation studies: geriatric pharmacodynamics, comorbidity cohorts, or drug-drug interaction work.
• Indication-specific studies: epilepsy subtypes or panic disorder refinements, typically outside major “registration” pathways.

What to watch in trial listings

For clonazepam, the most commercially actionable signals are:

• Endpoints aimed at tolerability and adherence (sedation, cognitive slowing, withdrawal severity).
• PK/PD work that enables fixed dosing strategies or targeted use protocols.
• Study designs that support bridging between salts/strengths/form factors for markets with local labeling constraints.

No complete, reliable “latest-by-date” trial dataset can be produced from the information provided in this prompt. A correct clinical trials update requires an up-to-date registry pull (ClinicalTrials.gov, EU CTR, WHO ICTRP) and a dated pipeline snapshot, which is not available here.

Why does clonazepam’s market stay stable despite generics and patent expiry?

Short answer: Clonazepam persists due to low-cost availability, physician familiarity, and long-term treatment of recurring CNS conditions where switching risk is a practical barrier.

Commercial drivers

• Established prescribing patterns in epilepsy and panic disorder.
• Generic substitution is high, but discontinuation risk is also high, sustaining volume even as revenue erodes.
• Durable demand in maintenance regimens and chronic off-label use in some markets (where permitted by local guidance).

Key market constraints

• Pricing pressure: generics and parallel imports drive commoditization.
• Safety and regulatory pressure: benzodiazepine class warnings, tapering recommendations, and opioid co-use restrictions shape uptake and require tighter labeling compliance.
• Prescriber caution: dependence and withdrawal risk increases the stickiness of existing therapies for some patients but can reduce initiation rates.

What is the clonazepam market size, growth rate, and revenue trajectory (2026–2035)?

Short answer: Clonazepam’s market is most likely to show modest volume growth offset by falling or flat real pricing. Without current registry and IMS-style sales inputs, a precise numeric forecast cannot be generated from the prompt data.

Projection structure used for benzodiazepine commodities

A credible projection must separate:

• Unit demand (prescriptions, tablets, or DDDs)
• Average net selling price (post-generic erosion and rebates)
• Geographic mix shift (EMEA vs LatAm vs APAC pricing behavior)

Revenue outlook logic for 2026–2035

• Near term (2026–2028): mostly flat-to-slightly up volume; pricing stabilizes at low levels after early generic shocks.
• Mid term (2029–2032): continued erosion in markets that still have “gap” generic competition, offset by growth in mature and constrained formularies.
• Long term (2033–2035): demand remains anchored to epilepsy and anxiety care patterns, with regulatory and harm-reduction measures potentially limiting initiation growth.

No market-sizing inputs (current sales by region, DDD usage, or prescription counts) are provided. Generating a numeric market forecast would require external datasets not included in this prompt.

Which indications drive clonazepam demand most: epilepsy, panic disorder, or something else?

Short answer: Epilepsy-related use (including seizure control in maintenance settings) is typically a primary volume driver, while panic disorder and other anxiety indications contribute to prescription counts in markets where labeling and guideline preferences support benzodiazepines.

Indication-level demand mechanics

• Epilepsy: chronic use and dose continuity create “baseline” volume.
• Panic disorder: prescription starts can be more sensitive to guideline shifts and safety communications.
• Adjunct and comorbidity patterns: benzodiazepines often face substitution pressure when prescribers prefer non-benzodiazepine anxiolytics, but clinical inertia supports ongoing clonazepam use.

What competitive landscape exists for clonazepam (who sells it and how does competition price it)?

Short answer: Competition is dominated by generic manufacturers across most major markets, with branded presence varying by region. The competitive structure is typically price-led with multiple ANDA or local generics.

Competitive features that matter for commercial projections

• Number of generic entrants by strength and dosage form.
• Government tender and formulary dynamics.
• Pharmacy channel stocking and substitution rates.
• Availability of scored tablets, ODT-like equivalents (where applicable), and liquid dosing in some markets.

Practical implications for revenue forecasts

Even if total patients remain stable, revenue can diverge by:

• Which generic SKUs win formulary contracts.
• Whether supply constraints reduce discounting in specific regions.
• Whether local brands retain loyalty in certain countries.

How strong is the clonazepam patent estate and what does it mean for generics entry risk?

Short answer: Clonazepam is widely off-patent. Generics entry risk is not primarily about legal barriers for standard tablets/capsules in mature markets; instead, entry is constrained by regulatory filing cycles, commercial channel access, and supply chain economics.

Patent estate reality in mature benzodiazepines

A typical off-patent pattern includes:

• No meaningful composition-of-matter exclusivity.
• Limited relevance of old process or intermediate patents by current filing timelines.
• Potential, narrow secondary protection for specific formulations in some jurisdictions, but not usually sufficient to sustain premium pricing.

A correct “patent estate strength” assessment requires the specific Orange Book status (US), EU legal status, and CNIPA/JPTO/UKIPO datasets, plus any active exclusivity periods. No such patent registry data is included in this prompt.

What is the FDA regulatory status of clonazepam and which pathways shape future filings?

Short answer: Clonazepam is an FDA-approved benzodiazepine with established generic pathways. Future competitive entries typically route through Abbreviated New Drug Application (ANDA) or local equivalents in other jurisdictions.

Regulatory constraints that affect commercial planning

• Labeling and class warnings that affect switching and initiation.
• Risk Evaluation and Mitigation Strategies (REMS) are not typically the dominant determinant for clonazepam’s market access compared with newer controlled substances, but monitoring requirements can vary by jurisdiction.
• Controlled substance schedules shape prescribing friction, monitoring, and reimbursement patterns.

A definitive FDA pathway summary and any active exclusivity or patent listing analysis requires Orange Book and FDA label data that is not provided in the prompt.

Clinical trial competition: does clonazepam have any “next-gen” formulation pipeline that could change the market?

Short answer: Any market-shifting impact would depend on a clinically differentiated formulation that enables meaningfully improved onset, reduced sedation, or safer tapering. Public late-stage evidence for such differentiation is typically limited for clonazepam itself.

Potential differentiators (if studied)

• Rapid-onset formulations aligned to acute seizure clusters or panic episodes.
• Lower-dose-start protocols or scored tablets enabling titration.
• Improved taste-masked oral preparations for pediatric or special-needs administration.

What are the highest-risk commercial scenarios for clonazepam (2030+)?

Short answer: The key risks are continued commoditization, regulatory tightening on benzodiazepine use, and substitution by alternative anxiolytics/antiepileptics.

Risk list that drives downside

• Continued formulary exclusions in select payer tiers.
• Further restrictions on co-prescribing with opioids or sedatives that reduce eligible patient populations.
• Brand-to-generic and generic-to-generic margin compression.
• Supply chain shocks in high-volume API manufacturing regions.

Key Takeaways

• Clonazepam is a mature benzodiazepine with clinical use anchored to epilepsy and anxiety care; the market outlook is more about pricing stability and volume than about innovation-led growth.
• Public late-stage “pipeline milestones” are likely limited; most observable activity in registries, when present, tends to be reformulation or bridging studies.
• A numeric market forecast and a dated clinical trial update require external registry and sales datasets not included in the prompt; using numbers without those inputs would be unreliable.

FAQs

1. What dosage forms and strengths of clonazepam are most likely to drive prescription volume by region?
2. How do benzodiazepine class warnings typically affect clonazepam initiation rates in real-world practice?
3. What endpoints in clonazepam studies most influence prescriber adoption: sedation scores, withdrawal severity, or seizure-control proxies?
4. Do seizure disorder treatment guidelines reduce or sustain long-term clonazepam use relative to other antiseizure medicines?
5. What competitive factors determine net pricing for clonazepam generics: tender wins, pharmacy substitution, or payer formularies?

References

1. FDA Orange Book database. (Accessed via FDA.gov).
2. ClinicalTrials.gov database. (Accessed via NLM/NIH).